Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma

Annals of Hematology

Volumn 89, Issue 3, 2010, Pages 263-272

  Tsirigotis, Panagiotis ^a   Dray, Liliane ^a   Resnick, Igor B ^a   Ackerstein, Aliza ^a   Gesundheit, Benjamin ^a   Elad, Sharon ^a   Or, Reuven ^a   Shapira, Michael Yechiel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Autologous bone marrow transplantation; Immunotherapy; Maintenance; Relapse; Rituximab

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2; MELPHALAN; NAVELBINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REPEATED DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; AUTOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949319264     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0808-5     Document Type: Article

References (32)

1. Tsirigotis P, Economopoulos T (2008) Monoclonal antibodies in the treatment of lymphoid malignancies. J Steroid Biochem Mol Biol 108:267-271
2. Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S et al (1999) Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 26:115-122
3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545
4. Smith SM, Grinblatt D, van Besien K (2002) Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy 4:223-240
5. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
6. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE et al (2005) Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661
7. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
8. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732
9. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423
10. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927-1932
11. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
12. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
13. Gisselbrecht C (2008) Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haemato 143:607-621
14. Belhadj K, Delfau-Larue MH, Elgnaoui T, Beaujean F, Beaumont JL, Pautas C et al (2004) Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol 15:504-510
15. Rohatiner A, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223
16. Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S (1997) Immunotherapy with recombinant human interleukin-2 and recombinant interferon-a in lymphoma patients postautologous marrow or stem cell transplantation. Blood 89:3951-3959
17. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P et al (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23:2240-2247
18. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE et al (2004) Rituximab as adjuvant to highdose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777-783
19. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B et al (2002) Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 29:303-312
20. Haioun C, Mounier N, Emile JF, Bologna S, Coiffier B, Tilly H et al (2007) Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study. J Clin Oncol 25:444s (Abstract 8012)
21. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al (2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19:406-413
22. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P et al (2009) Allogeneic stem cell transplantation for patients with relapsed chemorefractory non-Hodgkin lymphomas. Biol Blood Marrow Transplant 15:547-553
23. Doocey RT, Toze CL, Connors JM, Nevill J, Gascoyne RD, Barnett MJ et al (2005) Allogeneic haematopoietic stem cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131:223-230
24. Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F et al (2004) Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non- Hodgkin's lymphoma. Bone Marrow Transplant 33:921-923
25. Lee MY, Chiou TJ, Hsiao LT, Yang MH, Lin PC, Poh SB et al (2008) Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 87:285-289
26. Fernandez HF, Escalon MP, Pereira D, Lazarus HM (2007) Autotransplant conditioning regimens for aggressive B-cell lymphoma: are we on the right road? Bone Marrow Transplant 40:505-513
27. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M (2008) Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 49:1329-1336
28. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127
29. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A et al (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688
30. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM (2008) Time to relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant 41:715-720
31. Holmberg LA, Maloney D, Bensinger W (2006) Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 7:135-139
32. Tsai D, Moore H, Hardy C, Porter D, Loh E, Vaughn D et al (1999) Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 24:521-526